BRAF and colorectal cancer: The BEACON trial showed that combination targeted therapy with encorafenib and cetuximab was associated with prolonged survival in patients with metastatic BRAF variant colorectal cancer.2 However, the results of this economic evaluation suggested that doublet therapy was unlikely to represent a cost-effective treatment strategy compared with cetuximab and chemotherapy, with an ICER exceeding $500 000 per QALY gained.